CN1121395C - 类视色素作用增强性化合物 - Google Patents

类视色素作用增强性化合物 Download PDF

Info

Publication number
CN1121395C
CN1121395C CN96198386A CN96198386A CN1121395C CN 1121395 C CN1121395 C CN 1121395C CN 96198386 A CN96198386 A CN 96198386A CN 96198386 A CN96198386 A CN 96198386A CN 1121395 C CN1121395 C CN 1121395C
Authority
CN
China
Prior art keywords
compound
dimethyl
alkyl
hexylidene
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96198386A
Other languages
English (en)
Chinese (zh)
Other versions
CN1202160A (zh
Inventor
首藤絋一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R and R Inc
Original Assignee
Pharmaceutical Molecular Design Institute Co ltd
Nikken Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Molecular Design Institute Co ltd, Nikken Chemicals Co Ltd filed Critical Pharmaceutical Molecular Design Institute Co ltd
Publication of CN1202160A publication Critical patent/CN1202160A/zh
Application granted granted Critical
Publication of CN1121395C publication Critical patent/CN1121395C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thin Film Transistor (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN96198386A 1995-09-21 1996-09-20 类视色素作用增强性化合物 Expired - Fee Related CN1121395C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP242639/95 1995-09-21
JP24263995 1995-09-21
JP242639/1995 1995-09-21
JP150582/1996 1996-06-12
JP15058296 1996-06-12
JP150582/96 1996-06-12

Publications (2)

Publication Number Publication Date
CN1202160A CN1202160A (zh) 1998-12-16
CN1121395C true CN1121395C (zh) 2003-09-17

Family

ID=26480129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198386A Expired - Fee Related CN1121395C (zh) 1995-09-21 1996-09-20 类视色素作用增强性化合物

Country Status (13)

Country Link
US (3) US5929069A (OSRAM)
EP (1) EP0906907B1 (OSRAM)
KR (1) KR100484294B1 (OSRAM)
CN (1) CN1121395C (OSRAM)
AT (1) ATE214055T1 (OSRAM)
AU (1) AU7001596A (OSRAM)
CA (1) CA2233012A1 (OSRAM)
DE (1) DE69619711T2 (OSRAM)
DK (1) DK0906907T3 (OSRAM)
EA (1) EA002123B1 (OSRAM)
NO (1) NO981269L (OSRAM)
TW (1) TW420667B (OSRAM)
WO (1) WO1997011061A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0906907T3 (da) * 1995-09-21 2002-04-22 Inst Med Molecular Design Inc Forbindelser, der potenserer retinoid
CA2309331A1 (en) * 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Agent acting on retinoid receptor
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4314000A (en) 1999-04-28 2000-11-17 Institute Of Medicinal Molecular Design. Inc. Heterocyclic carboxylic acid derivatives
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
EP2062583B1 (en) * 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
WO2004083413A1 (ja) * 2003-03-20 2004-09-30 Research Foundation Itsuu Laboratory 器官形成方法
GB0308335D0 (en) * 2003-04-10 2003-05-14 Novartis Ag Organic compounds
KR20070007818A (ko) 2004-03-10 2007-01-16 재단법인 이쯔우 연구소 기억 고정 촉진제
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び／又は治療のための医薬
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
CN101262861B (zh) 2005-09-09 2011-04-06 有限会社肯菲思 用于预防及/或治疗肠疾病的药物
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008081427A (ja) * 2006-09-27 2008-04-10 R&R Inc 分泌障害性疾患の予防及び／又は治療のための医薬
US7902260B2 (en) * 2007-02-28 2011-03-08 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom
JP5383513B2 (ja) 2007-03-09 2014-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 化合物およびその標的に関連する組成物ならびに方法
CN101821229B (zh) 2007-08-15 2013-06-05 财团法人乙卯研究所 三环类胺化合物
WO2009036175A2 (en) 2007-09-14 2009-03-19 The Regents Of The University Of Michigan F1f0-atpase inhibitors and related methods
RU2010122902A (ru) 2007-11-06 2011-12-20 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Бензодиапениноновые соединения, применимые в лечении кожных состояний
EP2352724B1 (en) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryl guanidine f1f0-atpase inhibitors and their medical use
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
EP2484672B1 (en) 2009-09-28 2015-07-15 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and salt thereof, and herbicide for agricultural and horticultural use
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US20130324520A1 (en) * 2011-02-14 2013-12-05 Sloan-Kettering Institute For Cancer Research Rxrg modulators for the treatment of cancer
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
KR200489267Y1 (ko) 2018-09-20 2019-05-23 김은진 폭 조절형 옷걸이
KR200490993Y1 (ko) 2019-06-14 2020-02-04 이현봉 구김방지기능을 구비한 바지걸이
CN114702454A (zh) * 2022-03-29 2022-07-05 江西师范大学 5-烷基-11-芳基-5H-二苯并[b,e][1,4]二氮杂卓衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
DK0906907T3 (da) * 1995-09-21 2002-04-22 Inst Med Molecular Design Inc Forbindelser, der potenserer retinoid
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CA.VOL.66 1967-01-01;J.MED,CHEM.COL37.NO.10 1994-05-13 *
J.ORG.CHEM.VOL.37.NO.24. 1972-01-01 *

Also Published As

Publication number Publication date
EP0906907B1 (en) 2002-03-06
CN1202160A (zh) 1998-12-16
EA199800318A1 (ru) 1998-10-29
CA2233012A1 (en) 1997-03-27
EP0906907A4 (OSRAM) 1999-04-07
ATE214055T1 (de) 2002-03-15
KR19990063661A (ko) 1999-07-26
US6476017B2 (en) 2002-11-05
DK0906907T3 (da) 2002-04-22
WO1997011061A1 (en) 1997-03-27
NO981269D0 (no) 1998-03-20
EP0906907A1 (en) 1999-04-07
US6121256A (en) 2000-09-19
NO981269L (no) 1998-05-20
US5929069A (en) 1999-07-27
US20010039272A1 (en) 2001-11-08
DE69619711T2 (de) 2002-10-17
KR100484294B1 (ko) 2005-09-09
TW420667B (en) 2001-02-01
AU7001596A (en) 1997-04-09
DE69619711D1 (de) 2002-04-11
EA002123B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
CN1121395C (zh) 类视色素作用增强性化合物
CN1065536C (zh) 2－甲基－噻吩并苯并二氮杂䓬的结晶形式及制备方法
CN1059674C (zh) 降低血脂的苯并硫氮杂䓬
JP4929472B2 (ja) カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
CN1264817C (zh) 环状硫取代的酰基氨基酸酰胺衍生物
CN1186315C (zh) o－茴香酰胺衍生物
CN1077885C (zh) 联苯基磺酰胺基质金属蛋白酶抑制剂
CN1279673A (zh) (环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1019668B (zh) 喹诺酮羧酸衍生物的制备方法
CN1812963A (zh) 用于治疗阿尔茨海默病的N－烷基苯基甲酰胺β分泌酶抑制剂
CN1144806C (zh) 噻吩并嘧啶化合物
JPH10338658A (ja) レチノイド作用調節剤
CN1027369C (zh) 兴奋性氨基酸拮抗剂的制备方法
CN100357280C (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1247511C (zh) 环庚三烯酚酮衍生物
JP3865829B2 (ja) レチノイド作用増強性化合物
CN1307567A (zh) 1,5－苯并二氮杂䓬类衍生物
CN1070190A (zh) 杂环取代的喹啉甲氧基苯乙酰胺
CN1022241C (zh) 3-酰基-2-氧代吲哚-1-羧酰胺抗炎剂的前药化合物的制备
JP4005160B2 (ja) レチノイドアンタゴニスト
CN1027066C (zh) 吲哚衍生物的制备方法
CN1230948A (zh) 吡喃并吲哚和咔唑cox－2抑制剂
CN102046639A (zh) 新类别的GABAA/BzR配体
CN1281592C (zh) 1,2,4－苯并噻二嗪－1,1－二氧代化合物的制备方法
CN1087338A (zh) 治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Medicinal Mocule Design & Research Inst. Co. Ltd.

Applicant before: Shudo Koichi

Co-applicant before: Chemical Co Ltd

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SHOUTENG YI TO: DRUG MOLECULAR DESIGN INSTITUTE CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BE KENPHIS CO.,LTD

Free format text: FORMER OWNER: DRUG MOLECULAR DESIGN INSTITUTE CO., LTD.

Effective date: 20071026

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20071026

Address after: Tokyo, Japan

Patentee after: R. & R. Inc.

Address before: Tokyo, Japan, Japan

Patentee before: Medicinal Mocule Design & Research Inst. Co. Ltd.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030917

Termination date: 20110920